Patent · US Active

Fibronectin based scaffold proteins

US11447538B2 · kind B2 · utility

0Cited by

16References

8Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Dasa Lipovsek · Pepperell, US
Jonathan Davis · Waltham, US

Key dates

Filing date	Jan 10, 2020
Grant date	Sep 20, 2022
Priority date	—
Expiry date	Jul 8, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.